The COHCCC Protocol Review and Monitoring System is implemented through the activities of its Cancer Protocol Review and Monitoring Committee (CPRMC). The CPRMC focuses on scientific merit, scientific priorities, and scientific progress of Cancer Center clinical research, working collaboratively with the Data and Safety Monitoring Committee (DSMC) in accordance with the COHCCC Data and Safety Monitoring Plan. The role of the CPRMC is to: 1) maintain and improve the quality of institutional clinical research;2) prioritize clinical research conducted by Cancer Center members;and 3) provide a pathway for innovative clinical cancer research to access Cancer Center shared resources and protocol specific research support. Committee review and voting is required for all new trials, amendments, and annual continuation reviews. The scientific review process for new trials includes an evaluation of study design, scientific rationale, feasibility and biostatistical methodology. Annual continuation reviews include an examination of actual vs. expected accrual and continued relevance of the research question. The CPRMC provides a centralized mechanism for evaluating the scientific merit of all cancer clinical trials and prioritizes studies for access to COHCCC clinical trial resources. Funding is requested for partial salary support for the Chair of the CPRMC, the Director of Scientific and Safety Review, two Protocol Analysts and a Clerical Specialist supporting the work of protocol review and monitoring. All other remaining costs are covered by institutional funds.
It is of critical importance that the COHCCC have a mechanism for assuring adequate internal oversight of the scientific aspects of all cancer clinical trials. The PRMS addresses this. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.
|Kuo, Ching-Ying; Cheng, Chun-Ting; Hou, Peifeng et al. (2016) HIF-1-alpha links mitochondrial perturbation to the dynamic acquisition of breast cancer tumorigenicity. Oncotarget 7:34052-69|
|Nakamura, Ryotaro; La Rosa, Corinna; Longmate, Jeffrey et al. (2016) Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematol 3:e87-98|
|Wittenberg, Elaine; Ferrell, Betty; Goldsmith, Joy et al. (2016) Family Caregiver Communication Tool: a new measure for tailoring communication with cancer caregivers. Psychooncology :|
|Zhou, Ting; Pan, Feiyan; Cao, Yan et al. (2016) R152C DNA Pol Î² mutation impairs base excision repair and induces cellular transformation. Oncotarget 7:6902-15|
|Sun, Virginia; Ruel, Nora; Chung, Vincent et al. (2016) Pilot study of an interdisciplinary supportive care planning intervention in pancreatic cancer. Support Care Cancer 24:3417-24|
|Li, Zhongqi; Oganesyan, Diana; Mooney, Rachael et al. (2016) L-MYC Expression Maintains Self-Renewal and Prolongs Multipotency ofÂ Primary Human Neural Stem Cells. Stem Cell Reports 7:483-95|
|Reid, Michael A; Lowman, Xazmin H; Pan, Min et al. (2016) IKKÎ² promotes metabolic adaptation to glutamine deprivation via phosphorylation and inhibition of PFKFB3. Genes Dev 30:1837-51|
|Leung, Amy; Trac, Candi; Du, Juan et al. (2016) Persistent Chromatin Modifications Induced by High Fat Diet. J Biol Chem 291:10446-55|
|Thomas, Carissa M; Saulnier, Delphine M A; Spinler, Jennifer K et al. (2016) FolC2-mediated folate metabolism contributes to suppression of inflammation by probiotic Lactobacillus reuteri. Microbiologyopen 5:802-818|
|Champer, Jackson; Ito, James I; Clemons, Karl V et al. (2016) Proteomic Analysis of Pathogenic Fungi Reveals Highly Expressed Conserved Cell Wall Proteins. J Fungi (Basel) 2:|
Showing the most recent 10 out of 1181 publications